Profile
Dr Boon Cher GOH
Collaborator
Dr Goh received his undergraduate medical education at the National University of Singapore, and joined the Department of Hematology-Oncology, NUH where he completed his fellowship in medical oncology, and a National Medical Research Council fellowship in clinical pharmacology and phase I clinical trials at the University of Chicago.
Since then he has established himself as a leading clinician scientist in clinical pharmacology and cancer drug development, and currently serves on several institutional and national research portfolios. Upon his return from Chicago, he has contributed much to the development of a clinical trial research infrastructure at the NCIS, one of the largest clinical research groups in Singapore, and chaired the Cancer Therapeutics Research Group, an Asia Pacific cancer research group. He is principal investigator of the Experimental therapeutics group at the Cancer Science Institute, Singapore focused on evaluating novel treatments for cancer. As a clinician, he is well established in the fields of head and neck/lung cancer.
As a senior clinician and scientist, he has mentored many clinical oncology and pharmacology fellows, and has been awarded senior clinician scientist from the Biomedical Research Council and the National Medical Research Council since 2005. In addition, he has been competitive in being awarded research grants as principal investigator of both individual project grants and infrastructure grants.
Beyond cancer therapeutics, he is also widely published in pharmacogenetics, studying how human genetics affect drug response. Internationally, as a key opinion leader, he has served on advisory boards of several pharmaceutical companies advising on drug development of very novel drugs, and has served on editorial boards of important journals like the Journal of Clinical Oncology and Annals of Oncology.
As a responsible member of clinical research, he has also espoused principles of ethics, and served for several terms as Chairman of the Domain Specific Research Board.
Dr Goh currently holds the position of Group Chief Physician Leadership and Organisation Development Officer at the National University Health System. He is also the Deputy Director (Research) at the National University Cancer Institute, Singapore.
boon_cher_goh@nuhs.edu.sg
Singapore
Collaborators
BloodCounts!
Research Interest
Key Publications
Google Scholar Link
Kong LR, Ong RW, Tan TZ, Mohamed Salleh NAB, Thangavelu M, Chan JV, Koh LYJ, Periyasamy G, Lau JA, Le TBU, Wang L, Lee M, Kannan S, Verma CS, Lim CM, Chng WJ, Lane DP, Venkitaraman A, Hung HT, Cheok CF, Goh BC. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation. Nat Commun. 2020 Apr 29;11(1):2086. doi: 10.1038/s41467-020-15608.
Kong LR, Mohamed Salleh NAB, Ong RW, Tan TZ, Syn NL, Goh RM, Fhu CW, Tan DSW, Iyer NG, Kannan S, Verma CS, Lim YC, Soo R, Ho J, Huang Y, Lim JSJ, Yan BJ, Nga ME, Lim SG, Koeffler HP, Lee SC, Kappei D, Hung HT, Goh BC. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma. Nat Commun. 2020 Mar 25;11(1):1556. doi: 10.1038/s41467-020-15318-5.
Thuya WL, Kong LR, Syn NL, Ding LW, Cheow ESH, Wong RTX, Wang T, Goh RMW, Song H, Jayasinghe MK, Le MT, Hu JC, Yong WP, Lee SC, Wong AL, Sethi G, Hung HT, Ho PC, Thiery JP, Sze SK, Guo T, Soo RA, Yang H, Lim YC, Wang L, Goh BC. FAM3C in circulating tumor-derived extracellular vesicles promotes non-small cell lung cancer growth in secondary sites. Theranostics. 2023 Jan 1;13(2):621-638. doi: 10.7150/thno.72297
Hirpara J, Thuya WL, Cheow SH, Fernando K, Eu JQ, Wang L, Wong AL, Fong ELS, Ali AB, Ding LW, Zhuoran W, Lim YC, Pervaiz S, Goh BC. Tumor-derived extracellular vesicles convey solute transporters to induce bioenergetic dependence shift contributing to treatment resistance. Theranostics. 2024 Sep 30;14(16):6350-6369. doi: 10.7150/thno.100374.
Wan-Qin Chong, Jia-Li Low, Joshua K Tay, Thi Bich Uyen Le, Grace Shi-Qing Goh, Hui-Lin Teo, Kenneth Sooi, Regina Tong-Xin Wong, Jens Samol, Ming-Yann Lim, Hao Li, Niranjan Shirgaonkar, Shumei Chia, Anil Gopinathan, Donovan Kum-Chuen Eu, Raymond King-Yin Tsang, Kwok-Seng Loh, Han-Chong Toh, Nicholas Syn, Li-Ren Kong, Ramanuj Dasgupta, Bee-Choo Tai, Yaw-Chyn Lim, Boon-Cher Goh. Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial. Lancet Oncol. 2025 Feb;26(2):175-186. doi: 10.1016/S1470-2045(24)00677-6
Internal Comments Only
Achievements
- NUHS-Mochtar Riady Pinnacle Awards 2015 - Translational Research Innovator Award
- National Day Award – the Public Administration Medal (Bronze) – 2019
- Pharmacological Society (Singapore) Excellence Award in Pharmacology Research 2019
- National Medical Excellence Award – National Outstanding clinician scientist award 2019
- NMRC – Singapore Translational Research Investigator 2021
- Ministry of Health Distinguished Senior clinician award (2023)